Month: March 2022

TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) —  China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it entered into a securities purchase agreement to issue  a convertible promissory note in the original principal amount of $2,804,848.00 to Streeterville Capital, LLC, a Utah limited liability company. The 12-month note shall bear interest at the rate of 6% per annum. Any time after ninety (90) days of issuance, the investor may elect to...

Figure 1 Figure shows NVRO internally assessed relative project potential for top tailings reprocessing projects.TORONTO, March 14, 2022 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: RGOZF |FSE: YGK) (“EnviroGold Global” or the “Company“), a Clean Technology Company accelerating the world’s transition to a circular-resource economy through the production of Metals Without Mining, is pleased to provide an update on expected near-term growth milestones and the development of the Company’s global tailings reprocessing pipeline as key milestones are achieved on the way to commercial production of precious metals (gold, silver) clean-energy and battery metals (copper, zinc, lead) in 2022. The Company previously announced that the metals produced at its Hellyer Tailings Reprocessing Project and Buchans Tailings...

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the Company won its false advertising case against Natera (Nasdaq: NTRA) as a jury found that Natera and its senior executives intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. CareDx was awarded monetary damages totaling $44.9M:...

New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomas nextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumabSYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) — Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer. nextHERIZON is an open-label, multi-center,...

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023 Lecanemab collaboration to continue unchanged globally Lecanemab supply agreement to extend to 10 years from 5 years for commercial manufacturing by Biogen Both companies will continue to collaborate together with the goal of bringing more options to patients and maximizing the value of both productsCAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of...

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts First clinical data demonstrating effectiveness of HGNS to treat CCC patients  As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months, and reports 60%+ responder rates for all three cohorts  Exceeds 70% mean reduction in AHI4 among responders in both CCC and non-CCC cohortsMont-Saint-Guibert, Belgium – March 14, 2022, 11:30pm CET / 6:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided additional data from its BETTER SLEEP clinical trial that it showcased in a poster presentation at the 16th World...

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Cardinal Energy Ltd. (“Cardinal” or the “Company“) (TSX: CJ) is pleased to announce its operating and financial results for the fourth quarter and year ended December 31, 2021. FINANCIAL HIGHLIGHTS FROM THE FOURTH QUARTER OF 2021Fourth quarter 2021 production increased 10% over the same period in 2020; In the fourth quarter of 2021, adjusted funds flow(1) increased 293% to $53.5 million ($0.36 per basic share) as compared to the fourth quarter of 2020. Adjusted funds flow(1) for 2021 increased to $132.5 million, a 202% increase over 2020; West Texas Intermediate (“WTI”) oil prices averaged approximately US$77/bbl resulting in free cash flow(1) of $35.4 million in the fourth quarter of 2021 contributing to a fourth quarter net debt(1) reduction...

MONTREAL, March 14, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on March 10, 2022 with certain institutional and accredited investors. In connection with the private placement, the Company issued (i) 2,301,353 shares of its Common Stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of Common Stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Investor Warrants to purchase up to 1,302,251...

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B convertible preferred stock and Series A warrants to purchase up to an aggregate of 24,250,000 shares of common stock and Series B warrants to purchase up to an aggregate of 24,250,000 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.20 per share. The shares of preferred stock issued in the offering are convertible into...